Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE: Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Trials
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 27 Jun 2017 Planned End Date changed from 1 Mar 2017 to 1 Aug 2018.
- 27 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Aug 2018.
- 29 Sep 2016 New trial record